The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Johnston, S. R. D., Hegg, R., Im, S.-A., Park, I. H., Burdaeva, O., Kurteva, G., Press, M. F., Tjulandin, S., Iwata, H., Simon, S. D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.7824 · Cited by 165
Self-citationRetractedAllemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., Bonaventure, A., Valkov, M., Johnson, C. J., Estève, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33326-3 · Cited by 6,145
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Self-citationFoulkes, W. D., Smith, I. E., & Reis-Filho, J. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra1001389 · Cited by 4,157
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Self-citationPalbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007 · cited 1×
“The toxicity pro fi les of these three drugs are slightly different, 25-30 and patients who develop severe toxicity characteristic of one CDK4/6 inhibitor may switch to a different CDK4/6 inhibitor.”
BackgroundSelf-citationEverolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863 · cited 5×
“34 In patients who relapsed on adjuvant AI therapy, or within 12 months of stopping adjuvant AI, a CDK4/6 inhibitor in combination with fulvestrant is advised [ESMO-MCBS v1.”
BackgroundInfluentialSelf-citationAlpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622 · cited 2×
“…hyperglycaemia, rash, gastrointestinal (GI) toxicity (nausea, vomiting, loss of appetite, mucositis, diarrhoea) and fatigue, which led to dose reductions/ interruptions in w 70% and discontinuations in 25% of patients, 36 although no new safety signals were observed with longer follow-up.”
BackgroundInfluentialSelf-citationPertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Self-citationTalazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175
Self-citationRibociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
Self-citation3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Self-citationTrastuzumab deruxtecan in previously treated HER2-positive breast cancer
Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S.-B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914510 · Cited by 2,006
Self-citationCristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Self-citationCortes, J., Cescon, D. W., Rugo, H. S., Nowecki, Z., Im, S.-A., Yusof, M. M., Gallardo, C., Lipatov, O., Barrios, C. H., Holgado, E., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32531-9 · Cited by 1,796
Self-citationMONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I. H., Trédan, O., Chen, S.-C., Manso, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.6155 · Cited by 1,744
Self-citationSacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Bardia, A., Hurvitz, S. A., Tolaney, S. M., Loirat, D., Punie, K., Oliveira, M., Brufsky, A., Sardesai, S. D., Kalinsky, K., Zelnak, A. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028485 · Cited by 1,711
Self-citation5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.010 · Cited by 1,369 · cited 3×
“7 [18F]2-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography (PET)-CT may be used instead of CT and bone scans [II, B].(18,19)”
BackgroundMethodSelf-citationTucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer
Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., Lin, N. U., Borges, V., Abramson, V., Anders, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914609 · Cited by 1,326
Self-citationSchmid, P., Rugo, H. S., Adams, S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Henschel, V., Molinero, L., Chui, S. Y., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30689-8 · Cited by 1,216
Self-citationGuckenberger, M., Lievens, Y., Bouma, A. B., Collette, L., Dekker, A., deSouza, N. M., Dingemans, A.-M. C., Fournier, B., Hurkmans, C., Lecouvet, F. E., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30718-1 · Cited by 1,111
Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094
Tripathy, D., Im, S.-A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., Hurvitz, S. A., Chow, L., Sohn, J., Lee, K. S., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30292-4 · Cited by 1,025
Self-citationJohnston, S., Pippen, J., Pivot, X., Lichinitser, M., Sadeghi, S., Dieras, V., Gomez, H. L., Romieu, G., Manikhas, A., Kennedy, M. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3734 · Cited by 1,025
Overall survival with ribociclib plus endocrine therapy in breast cancer
Im, S.-A., Lu, Y.-S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., Chow, L., Sohn, J., Lee, K.-S., Campos-Gomez, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903765 · Cited by 1,001
Self-citationBlackwell, K. L., Burstein, H. J., Storniolo, A. M., Rugo, H., Sledge, G., Koehler, M., Ellis, C., Casey, M., Vukelja, S., Bischoff, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4437 · Cited by 942
Self-citationSwain, S. M., Miles, D., Kim, S.-B., Im, Y.-H., Im, S.-A., Semiglazov, V., Ciruelos, E., Schneeweiss, A., Loi, S., Monturus, E., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30863-0 · Cited by 922
Self-citationCarboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Tutt, A., Tovey, H., Cheang, M. C. U., Kernaghan, S., Kilburn, L., Gazinska, P., Owen, J., Abraham, J., Barrett, S., Barrett-Lee, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0009-7 · Cited by 912
Overall survival with ribociclib plus fulvestrant in advanced breast cancer
Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911149 · Cited by 865
Self-citationKaufman, B., Mackey, J. R., Clemens, M. R., Bapsy, P. P., Vaid, A., Wardley, A., Tjulandin, S., Jahn, M., Lehle, M., Feyereislova, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6847 · Cited by 843
Mateo, J., Chakravarty, D., Dienstmann, R., Jezdic, S., Gonzalez-Perez, A., Lopez-Bigas, N., Ng, C. K. Y., Bedard, P. L., Tortora, G., Douillard, J.-Y., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy263 · Cited by 815
Self-citationRobson, M. E., Tung, N., Conte, P., Im, S.-A., Senkus, E., Xu, B., Masuda, N., Delaloge, S., Li, W., Armstrong, A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz012 · Cited by 779 · cited 1×
“suggested improved OS in patients receiving olaparib who had not received prior ChT for metastatic disease.(81) Notably, over 40% of the control arm in each study received a platinum or PARP inhibitor after progression on study treatment.”
BackgroundSelf-citationMiles, D., Gligorov, J., André, F., Cameron, D., Schneeweiss, A., Barrios, C., Xu, B., Wardley, A., Kaen, D., Andrade, L., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.05.801 · Cited by 734
Self-citationKrop, I. E., Kim, S.-B., González-Martín, A., LoRusso, P. M., Ferrero, J.-M., Smitt, M., Yu, R., Leung, A. C. F., & Wildiers, H. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70178-0 · Cited by 724
Dickler, M. N., Tolaney, S. M., Rugo, H. S., Cortés, J., Diéras, V., Patt, D., Wildiers, H., Hudis, C. A., O'Shaughnessy, J., Zamora, E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0754 · Cited by 676
Self-citationESMO-magnitude of clinical benefit scale version 1.1
Cherny, N. I., Dafni, U., Bogaerts, J., Latino, N. J., Pentheroudakis, G., Douillard, J.-Y., Tabernero, J., Zielinski, C., Piccart, M. J., & de Vries, E. G. E. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx310 · Cited by 641
Le Rhun, E., Weller, M., Brandsma, D., Van den Bent, M., de Azambuja, E., Henriksson, R., Boulanger, T., Peters, S., Watts, C., Wick, W., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx221 · Cited by 637
Self-citationDykewicz, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/321805 · Cited by 636
André, F., Ciruelos, E. M., Juric, D., Loibl, S., Campone, M., Mayer, I. A., Rubovszky, G., Yamashita, T., Kaufman, B., Lu, Y.-S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.011 · Cited by 624
Self-citationSaura, C., Oliveira, M., Feng, Y.-H., Dai, M.-S., Chen, S.-W., Hurvitz, S. A., Kim, S.-B., Moy, B., Delaloge, S., Gradishar, W., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00147 · Cited by 604
Self-citationLe Rhun, E., Guckenberger, M., Smits, M., Dummer, R., Bachelot, T., Sahm, F., Galldiks, N., de Azambuja, E., Berghoff, A. S., Metellus, P., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.07.016 · Cited by 592
Self-citationPiccart, M., Hortobagyi, G. N., Campone, M., Pritchard, K. I., Lebrun, F., Ito, Y., Noguchi, S., Perez, A., Rugo, H. S., Deleu, I., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu456 · Cited by 574 · cited 1×
“45) in patients who had progressed on a nonsteroidal AI,(39) but there was no significant OS or quality of life (QoL) benefit.(40) None of the patients enrolled in this trial had previously received CDK4/6 inhibitors, although retrospective analyses suggest that prior exposure to CDK4/6 inhibitor therapy may not impac…”
ResultSelf-citationFourney, D. R., Frangou, E. M., Ryken, T. C., DiPaola, C. P., Shaffrey, C. I., Berven, S. H., Bilsky, M. H., Harrop, J. S., Fehlings, M. G., Boriani, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.3897 · Cited by 551
Bone health in cancer: ESMO Clinical Practice Guidelines
Coleman, R., Hadji, P., Body, J.-J., Santini, D., Chow, E., Terpos, E., Oudard, S., Bruland, Ø., Flamen, P., Kurth, A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.019 · Cited by 549
Lin, N. U., Borges, V., Anders, C., Murthy, R. K., Paplomata, E., Hamilton, E., Hurvitz, S., Loi, S., Okines, A., Abramson, V., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00775 · Cited by 544 · cited 2×
“epidermal growth factor receptor (EGFR), in combination with capecitabine/trastuzumab for patients with BMs.(61) Although this trial was conducted in patients who had previously received trastuzumab and T-DM1, the PFS and OS benefits demonstrated in patients with active or stable CNS metastases (HRs 0.”
BackgroundInfluentialSelf-citationESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu385 · Cited by 540 · cited 8×
“MBC after therapy for EBC tends to have a more aggressive tumour biology and a worse outcome compared with de novo MBC. 14,15 In a retrospective cohort study covering the period 1990-2010, 14 de novo MBC incidence rates remained constant whereas subsequent MBC decreased.”
BackgroundInfluentialSelf-citationChandarlapaty, S., Chen, D., He, W., Sung, P., Samoila, A., You, D., Bhatt, T., Patel, P., Voi, M., Gnant, M., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1279 · Cited by 494
Winer, E. P., Lipatov, O., Im, S.-A., Goncalves, A., Muñoz-Couselo, E., Lee, K. S., Schmid, P., Tamura, K., Testa, L., Witzel, I., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30754-3 · Cited by 489
Self-citationVan Poznak, C., Somerfield, M. R., Bast, R. C., Cristofanilli, M., Goetz, M. P., Gonzalez-Angulo, A. M., Hicks, D. G., Hill, E. G., Liu, M. C., Lucas, W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.1459 · Cited by 404
Bardia, A., Messersmith, W. A., Kio, E. A., Berlin, J. D., Vahdat, L., Masters, G. A., Moroose, R., Santin, A. D., Kalinsky, K., Picozzi, V., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.005 · Cited by 400
Rugo, H. S., Lerebours, F., Ciruelos, E., Drullinsky, P., Ruiz-Borrego, M., Neven, P., Park, Y. H., Prat, A., Bachelot, T., Juric, D., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00034-6 · Cited by 345
Self-citationRugo, H. S., Im, S.-A., Cardoso, F., Cortés, J., Curigliano, G., Musolino, A., Pegram, M. D., Wright, G. S., Saura, C., Escrivá-de-Romaní, S., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.7932 · Cited by 343
Self-citationESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., et al. (2014) · The Breast · doi:10.1016/j.breast.2014.08.009 · Cited by 338
Self-citationCaswell-Jin, J. L., Plevritis, S. K., Tian, L., Cadham, C. J., Xu, C., Stout, N. K., Sledge, G. W., Mandelblatt, J. S., & Kurian, A. W. (2018) · JNCI Cancer Spectrum · doi:10.1093/jncics/pky062 · Cited by 315
Diéras, V., Han, H. S., Kaufman, B., Wildiers, H., Friedlander, M., Ayoub, J.-P., Puhalla, S. L., Bondarenko, I., Campone, M., Jakobsen, E. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30447-2 · Cited by 311
Single agent versus combination chemotherapy for metastatic breast cancer
Carrick, S., Parker, S., Thornton, C., Ghersi, D., Simes, J., & Wilcken, N. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003372.pub3 · Cited by 305
Biganzoli, L., Battisti, N. M. L., Wildiers, H., McCartney, A., Colloca, G., Kunkler, I. H., Cardoso, M.-J., Cheung, K.-L., de Glas, N. A., Trimboli, R. M., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30741-5 · Cited by 298
Gao, J. J., Cheng, J., Bloomquist, E., Sanchez, J., Wedam, S. B., Singh, H., Amiri-Kordestani, L., Ibrahim, A., Sridhara, R., Goldberg, K. B., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30804-6 · Cited by 289
Cortés, J., Fumoleau, P., Bianchi, G. V., Petrella, T. M., Gelmon, K., Pivot, X., Verma, S., Albanell, J., Conte, P., Lluch, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4207 · Cited by 249
Self-citationMiles, D. W., Diéras, V., Cortés, J., Duenne, A.-A., Yi, J., & O'Shaughnessy, J. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt276 · Cited by 228
Self-citationRugo, H. S., Seneviratne, L., Beck, J. T., Glaspy, J. A., Peguero, J. A., Pluard, T. J., Dhillon, N., Hwang, L. C., Nangia, C., Mayer, I. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30109-2 · Cited by 226
Self-citationRimawi, M., Ferrero, J.-M., de la Haba-Rodriguez, J., Poole, C., De Placido, S., Osborne, C. K., Hegg, R., Easton, V., Wohlfarth, C., Arpino, G., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.7863 · Cited by 217
Piccart-Gebhart, M. J., Burzykowski, T., Buyse, M., Sledge, G., Carmichael, J., Lück, H.-J., Mackey, J. R., Nabholtz, J.-M., Paridaens, R., Biganzoli, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8399 · Cited by 216
Breast Cancer Statistics in the European Union: Incidence and Survival across European Countries
Dafni, U., Tsourti, Z., & Alatsathianos, I. (2019) · Breast Care · doi:10.1159/000503219 · Cited by 199
Gennari, A., Stockler, M., Puntoni, M., Sormani, M., Nanni, O., Amadori, D., Wilcken, N., D'Amico, M., DeCensi, A., & Bruzzi, P. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.5374 · Cited by 186
Self-citationMurthy, R., Borges, V. F., Conlin, A., Chaves, J., Chamberlain, M., Gray, T., Vo, A., & Hamilton, E. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30256-0 · Cited by 170
Bachelot, T., Filleron, T., Bieche, I., Arnedos, M., Campone, M., Dalenc, F., Coussy, F., Sablin, M.-P., Debled, M., Lefeuvre-Plesse, C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01189-2 · Cited by 161
Ettl, J., Quek, R. G. W., Lee, K. H., Rugo, H. S., Hurvitz, S. A., Gonçalvès, A., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martín, M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy257 · Cited by 153
Self-citationMalmgren, J. A., Mayer, M., Atwood, M. K., & Kaplan, H. G. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4529-5 · Cited by 147
Martín, M., Zielinski, C. C., Ruíz‐Borrego, M., Carrasco, E., Turner, N. C., Ciruelos, E., Muñoz-Mateu, M., Bermejo, B., Vila, M. M., Anton, A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.12.013 · Cited by 147
Self-citationYardley, D. A., Coleman, R., Conte, P., Cortés, J., Brufsky, A., Shtivelband, M. I., Young, R. R., Bengala, C., Ali, H. Y., Eakel, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy201 · Cited by 140
Self-citationPark, Y. H., Kim, T., Kim, G. M., Kang, S. Y., Park, I. H., Kim, J. H., Lee, K. E., Ahn, H. K., Lee, M. H., Kim, H., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30565-0 · Cited by 134
Self-citationSingle agent versus combination chemotherapy for metastatic breast cancer
Carrick, S. E., Parker, S., Thornton, C. E., Ghersi, D., Simes, J. R., & Wilcken, N. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003372.pub2 · Cited by 118
Jérusalem, G., Boer, R. H. D., Hurvitz, S. A., Yardley, D. A., Kovalenko, E. I., Ejlertsen, B., Blau, S. H., Özgüroğlu, M., Landherr, L., Ewertz, M., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2262 · Cited by 100
Self-citationEuropean trends in breast cancer mortality, 1980–2017 and predictions to 2025
Wojtyła, C., Bertuccio, P., Wojtyła, A., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.04.026 · Cited by 100
Cortés, J., Kim, S.-B., Chung, W.-P., Im, S., Park, Y. H., Hegg, R., Kim, M., Tseng, L.-M., Petry, V., Chung, C.-F., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.2087 · Cited by 95
Self-citationRobson, M. E., Ruddy, K. J., Im, S., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Li, W., Tung, N., Armstrong, A. C., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.06.023 · Cited by 93
Self-citationGyawali, B., de Vries, E. G. E., Dafni, U. G., Amaral, T. M. S., Barriuso, J., Bogaerts, J., Calles, A., Curigliano, G., Gomez‐Roca, C., Kiesewetter, B., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100117 · Cited by 79
Self-citationHortobágyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Hart, L., Campone, M., Petráková, K., Winer, E. P., Janni, W., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.2090 · Cited by 75
Self-citationModi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S., Tamura, K., André, F., Iwata, H., Ito, Y., Tsurutani, J., et al. (2021) · Cancer Research · doi:10.1158/1538-7445.sabcs20-pd3-06 · Cited by 63
Self-citationKomorowski, A. S., Warner, E., MacKay, H. J., Sahgal, A., Pritchard, K. I., & Jerzak, K. J. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.06.007 · Cited by 59
Cook, M. M., Rabadi, L. S. A., Kaempf, A. J., Saraceni, M. M., Savin, M. A., & Mitri, Z. I. (2020) · The Oncologist · doi:10.1002/onco.13609 · Cited by 59
Cortés, J., Cescon, D. W., Rugo, H. S., Im, S., Yusof, M. M., Gallardo, C., Lipatov, O. N., Barrios, C. H., Pérez-García, J. M., Iwata, H., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.2089 · Cited by 55
Self-citationHölzel, D., Eckel, R., Bauerfeind, I., Baier, B., Beck, T., Braun, M., Ettl, J., Hamann, U., Kiechle, M. B., Mahner, S., et al. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2428-0 · Cited by 52
Self-citationRozenblit, M., Mun, S., Soulos, P. R., Adelson, K. B., Pusztai, L., & Mougalian, S. S. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01394-y · Cited by 46
Use and Costs of Disease Monitoring in Women With Metastatic Breast Cancer
Accordino, M. K., Wright, J. D., Vasan, S., Neugut, A. I., Hillyer, G. C., Hu, J. C., & Hershman, D. L. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.6313 · Cited by 38
Turner‐Bowker, D. M., Hao, Y., Foley, C., Galipeau, N., Mazar, I., Krohe, M., GLOBE, D. R., & Shields, A. L. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1205005 · Cited by 30
Lee, C. I., Gold, L. S., Nelson, H. D., Chou, R., Ramsey, S. D., & Sullivan, S. D. (2014) · The Breast · doi:10.1016/j.breast.2014.11.009 · Cited by 25
Cited by
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
Cortés, J., Kim, S.-B., Chung, W.-P., Im, S.-A., Park, Y. H., Hegg, R., Kim, M. H., Tseng, L.-M., Petry, V., Chung, C.-F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2115022 · Cited by 1,175
Self-citationCapivasertib in Hormone Receptor–Positive Advanced Breast Cancer
Turner, N. C., Oliveira, M., Howell, S. J., Dalenc, F., Cortes, J., Gomez Moreno, H. L., Hu, X., Jhaveri, K., Krivorotko, P., Loibl, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2214131 · Cited by 813
Self-citationPascual, J., Attard, G., Bidard, F.-C., Curigliano, G., De Mattos-Arruda, L., Diehn, M., Italiano, A., Lindberg, J., Merker, J. D., Montagut, C., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.520 · Cited by 783
Self-citationBidard, F.-C., Kaklamani, V. G., Neven, P., Streich, G., Montero, A. J., Forget, F., Mouret-Reynier, M.-A., Sohn, J. H., Taylor, D., Harnden, K. K., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00338 · Cited by 777
Self-citationHurvitz, S. A., Hegg, R., Chung, W.-P., Im, S.-A., Jacot, W., Ganju, V., Chiu, J. W. Y., Xu, B., Hamilton, E., Madhusudan, S., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02420-5 · Cited by 687
Self-citation
Metadata
- Authors
- Gennari, A., André, F., Barrios, C. H., Cortés, J., de Azambuja, E., DeMichele, A., Dent, R., Fenlon, D., Gligorov, J., Hurvitz, S. A., Im, S.-A., Krug, D., Kunz, W. G., Loi, S., Penault-Llorca, F., Ricke, J., Robson, M., Rugo, H. S., Saura, C., Schmid, P., Singer, C. F., Spanic, T., Tolaney, S. M., Turner, N. C., Curigliano, G., Loibl, S., Paluch-Shimon, S., & Harbeck, N.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2021-12
- Volume
- 32
- Issue
- 12
- Pages
- 1475-1495
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W3207557929
- Cited by
- 1,417
- References
- 89
- FWCI
- 65.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.